Psilocybin-Research.comSearchable psilocybin and psilocin bibliometric database.Researcher index
Authors in the psilocybin and psilocin literature
Search researcher names, inspect publication history, find recurring topics, and create author watch alerts without collecting unverified contact lists.
Publication history
Chronic psilocin microdosing produces limited behavioral effects and does not enhance neurogenesis in ratsPharmacology Biochemistry and Behavior · 2026-10-01Assessing The Readiness of Psychiatrists in Louisiana to Incorporate Psilocybin into Clinical Practice-Lessons Learned from a State Underrepresented in Clinical Psychedelic Research.Psychedelic medicine (New Rochelle, N.Y.) · 2026-09-01TRIP - TReatment to Improve Depression and/or Anxiety Using Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance TherapyClinicalTrials.gov · 2026-08-12Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for Alcohol Use DisorderClinicalTrials.gov · 2026-08-12NeuroGuard: Psilocybin Trial for Preventing Chemo-induced NeuropathyClinicalTrials.gov · 2026-08-12A Phase 2a, Placebo-Controlled Randomized, Double-Blind Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Psilocybin Oral Solution in Adults With Generalized Anxiety DisorderClinicalTrials.gov · 2026-08-12Psilocybin Recovery Intervention for Stopping Methamphetamine UseClinicalTrials.gov · 2026-08-11Could Psilocybin Be the Key to Treating Anorexia? -Breaking the Mind's Most Stubborn LoopUnknown journal · 2026-08-10An Investigation of Strategies to Understand and Optimize the Antidepressant Effects of Psilocybin (The OPTIMIZE Study)ClinicalTrials.gov · 2026-08-10A Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant DepressionClinicalTrials.gov · 2026-08-10Safety, Tolerability, Outcomes of Psilocybin for Depression (STOP Depression) in Veterans With Spinal Cord InjuryClinicalTrials.gov · 2026-08-10A Phase III, Multicentre, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Treatment-resistant DepressionClinicalTrials.gov · 2026-08-10A Multicenter Phase 1 Safety and Tolerability Trial of Psilocybin in Healthy Older AdultsClinicalTrials.gov · 2026-08-10Microdosing psychedelics: What, why, when, and how often? Insights from an international survey of people who use psychedelics.The International journal on drug policy · 2026-08-07Impact of Psilocybin on Motor Function in Healthy Participants: A Phase 1, Randomised, Triple-Blind, Dose-Finding Study.CNS drugs · 2026-08-07Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin (NECTAR) in Aging and Alzheimer's DiseaseClinicalTrials.gov · 2026-08-07The Efficacy of Psilocybin Therapy for Depression in Parkinson's DiseaseClinicalTrials.gov · 2026-08-07Psilocybin-assisted therapy for treatment-resistant major depressive disorder in a public healthcare setting: a randomized controlled trial.Nature medicine · 2026-08-06Single Dose Psilocybin for a Post-surgical Trauma Inpatient Population for Pain, Mood, and Opioid Use DisorderClinicalTrials.gov · 2026-08-06An Exploratory Study of Feasibility, Efficacy, and Mechanisms of Mindfulness-Assisted Psychedelic TherapyClinicalTrials.gov · 2026-08-06A suite of engineered mice for interrogating psychedelic drug actions.Nature neuroscience · 2026-08-06Role of β-Arrestin2 Signaling in Neuropharmacological Effects of Psychedelic Drugs.ACS chemical neuroscience · 2026-08-05Precision Phenotyping of Behavioral Risk and Response to Electromagnetic and Psychedelic TherapiesClinicalTrials.gov · 2026-08-04Serotonergic psychedelics induce distinct patterns of metabolic activity and covariance within biologically informed rat brain networksNature Communications · 2026-08-03Psilocybin as a Treatment for Chronic Pain in SmokersClinicalTrials.gov · 2026-08-03Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST)ClinicalTrials.gov · 2026-07-30Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression: A Pilot Randomized Clinical TrialClinicalTrials.gov · 2026-07-30Activating Neuroplasticity to ENHANCE the Perception Box Expanding Effects of PsilocybinClinicalTrials.gov · 2026-07-29Convergent neuroimmune signaling underlying rapid antidepressant response to ketamine and psychedelics.Molecular psychiatry · 2026-07-28Changes in Self-awareness Induced by Psychoactive Substances: an Experimental Study With Psilocybin.ClinicalTrials.gov · 2026-07-28An Examination of Psilocybin Effects on Biomarkers of Longevity, Healthy Aging, and Purpose in LifeClinicalTrials.gov · 2026-07-24Psilocybin and Affective Function in Chronic Lower Back Pain DepressionClinicalTrials.gov · 2026-07-24A Randomized Double-masked Dose-controlled Trial to Assess the Tolerability, Safety, Subjective Experience, and Efficacy of Repeated Administration of Three Different Doses of Psilocybin Whole Mushroom for the Treatment of Obsessive-compulsive Disorder.ClinicalTrials.gov · 2026-07-23Effects of Psilocybin on Electrophysiology and the Dynamic Content of ThoughtClinicalTrials.gov · 2026-07-23A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Psilocybin in Adults With Major Depressive Disorder (MDD)ClinicalTrials.gov · 2026-07-23A Randomized, Double-Blind, Placebo-Controlled Mechanistic Study to Assess a Single Oral Dose of CYB003 in Participants With Major Depressive Disorder (MDD) and Moderate to Severe AnxietyClinicalTrials.gov · 2026-07-23Longitudinal neural and psychological changes following psilocybin under compassion imagery primingFrontiers in Human Neuroscience · 2026-07-22PRISMatic: A Phase 1b Randomized, Double-Armed, Parallel-Group, Placebo-Controlled Trial of Psilocybin Efficacy With or Without Pimavanserin PretreatmentClinicalTrials.gov · 2026-07-21The Efficacy of Psilocybin Therapy for Depression in Parkinson's DiseaseClinicalTrials.gov · 2026-07-20A Randomized, Double-Blind, Single Ascending Dose Study to Identify a Safe and Non-Psychedelic Dose of PsilocybinClinicalTrials.gov · 2026-07-17Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder: a Randomized Double-blind TrialClinicalTrials.gov · 2026-07-17Psilocybin in Chronic Low Back Pain: An Integrative Study of Lab-Based Mechanisms and Real-World Physical Therapy OutcomesClinicalTrials.gov · 2026-07-16Psilocybin's effect on human brain synaptic plasticity.Translational psychiatry · 2026-07-15Effect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Trauma-Related Major Depressive Disorder: Randomized Controlled TrialClinicalTrials.gov · 2026-07-14Psilocybin-Assisted Early Palliative Care for Demoralization and Chronic Pain: An Open-Label Pilot Study.medRxiv: the preprint server for health sciences · 2026-07-14Mechanistic Studies of Psilocybin in Headache DisordersClinicalTrials.gov · 2026-07-13Psilocybin bei Depression: Systematisches Review und Meta-Analyse zur antidepressiven WirksamkeitOSF · 2026-07-10PSilocybin Microdose for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site Phase 3 Double-blind, Placebo-controlled, Parallel-arm Clinical TrialClinicalTrials.gov · 2026-07-10Investigating the Mechanisms of the Effects of Psilocybin on Visual Perception and Visual Representations in the BrainClinicalTrials.gov · 2026-07-10The Effects of Psilocybin on Social ConnectednessClinicalTrials.gov · 2026-07-09Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: A Randomized Phase II Clinical Trial Comparing One Versus Two Psychedelic Doses of Psilocybin (PSI-1V2)ClinicalTrials.gov · 2026-07-09Psilocybin: Capturing Brain Mechanisms of Motivation and Neurocognition in Individuals With Opioid Use DisorderClinicalTrials.gov · 2026-07-09Psilocybin therapy for adult females with anorexia nervosa: pilot studyThe British Journal of Psychiatry · 2026-07-08Synthesis and Biological Evaluation of 4-Bromo-dimethyltryptamine (4-Br-DMT): A Synthetic Building Block for Future Analog Development.ACS omega · 2026-07-07The need for another tool: Australian healthcare professionals on the use of psilocybin for existential distress in people with cancerBMC Medicine · 2026-07-06Naturally Derived Psilocybin for Therapeutic Use: A Six-Criterion Framework for Evidence, Safety, and Benefit-Risk Considerations in Policy and Clinical DevelopmentBiomolecules · 2026-07-03Consciousness and Psilocybin Effects on Well-Being: The CoPEWell StudyClinicalTrials.gov · 2026-07-02Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive SymptomsClinicalTrials.gov · 2026-07-01An Open-Label Study of Single-Dose Psilocybin for Borderline Personality Disorder With Co-Occurring Major Depressive DisorderClinical Neuropharmacology · 2026-07-01Implementing psilocybin-assisted therapy in palliative care settings: A survey of stakeholdersPalliative Medicine · 2026-07-01Psilocybin restores behavior and 5-HT2A signaling while reducing microglial density after chronic traumatic brain injury in ratsCell Reports Medicine · 2026-07-01Evidence that 5-HT receptor signalling efficacy and not biased agonism differentiates serotonergic psychedelic from non-psychedelic drugs.British journal of pharmacology · 2026-07-01Psilocybin improves novel object recognition in a rat model of Fragile X Syndrome through the modulation of the BDNF/TrkB signaling pathway.Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology · 2026-07-01Acute dose-dependent effects of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) compared with 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin in a double-blind, placebo-controlled study in healthy participantsNeuropsychopharmacology · 2026-07-01Study Protocol for “Exploring the safety and therapeutic potential of psilocybin in the treatment of anorexia nervosa in adolescents and young adults”PLOS One · 2026-06-30Naturally Derived Psilocybin for Therapeutic Use: A Six-Criterion Framework for Evidence, Safety, and Benefit-Risk Considerations in Policy and Clinical DevelopmentUniversity of Groningen research database (University of Groningen / Centre for Information Technology) · 2026-06-295-HT2A Agonist Psilocybin in the Treatment of Tobacco Use DisorderClinicalTrials.gov · 2026-06-29Acute Effects of MDMA Co-administration on the Response to Psilocybin in Healthy SubjectsClinicalTrials.gov · 2026-06-25A Pilot Mechanistic RCT of Psilocybin With Mindfulness-based Therapy vs Support for Posttraumatic Stress Disorder (PTSD)ClinicalTrials.gov · 2026-06-25Psilocybin Administration With 5-HT1a BlockadeClinicalTrials.gov · 2026-06-25Mechanistic insights toward dissociating therapeutic from psychedelic effects: bridging the gap between psychedelic research and mental health careTranslational Psychiatry · 2026-06-23Effects of Psilocybin Microdosing on Cognition, Mood and Quality of Life: A Pilot StudyClinicalTrials.gov · 2026-06-23Psilocybin for PTSD With or Without Psychotherapy: A Pilot Study of Safety and EfficacyClinicalTrials.gov · 2026-06-22Psychedelics disrupt hierarchical cortical propagations in the default mode network of humans and mice.Proceedings of the National Academy of Sciences of the United States of America · 2026-06-16The Acute Effects of Psilocybin on Cognition, Memory, and Brain FunctionClinicalTrials.gov · 2026-06-15Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder: A Double-Blind, Dose-Comparison Concurrent Control Randomized TrialClinicalTrials.gov · 2026-06-15Psychedelics relax predictive processing in the post-acute period by remodeling cortico-cortical feedback circuits.bioRxiv: the preprint server for biology · 2026-06-15Psilocybin-assisted Physiotherapy for Refractory Motor Functional Neurological Disorder: A Randomized Dose-comparison Pilot Study (P7-17.001)Neurology · 2026-06-09Alcohol consumption and substance use among French medical students: A nationwide cross-sectional study: Consommation d'alcool et de substances chez les étudiants en médecine de France: une étude transversale nationale.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2026-06-09A Double Blind, Randomized Trial Investigating the Safety, Feasibility, and Mechanisms of Psychedelics in Healthy Older Adults With Low Well-being as Moderated by Biomarkers for Preclinical Alzheimer's DiseaseClinicalTrials.gov · 2026-06-08Multivariate Neural and Physiological Correlates of Psychedelic Sub-states: a Within-subjects, Healthy Volunteer Study With Experience-samplingClinicalTrials.gov · 2026-06-05A Multi-site Randomized Controlled Trial of Psilocybin for Treatment-Resistant Depression (TRD) in VeteransClinicalTrials.gov · 2026-06-05Correction to: Preliminary Evidence of Sleep Improvements Following Psilocybin Administration, and their Involvement in Antidepressant Therapeutic ActionCurrent Psychiatry Reports · 2026-06-05Prenatal stress, excitatory-inhibitory imbalance, and ADHD risk: a hypothesis-driven perspective on psilocybin-induced neuroplasticityTranslational Psychiatry · 2026-06-05Effects of Repeated Dosing of Psilocybin on Obsessive-Compulsive Disorder: A Randomized, Waitlist-Controlled StudyClinicalTrials.gov · 2026-06-042 x 2 Factorial, Double-blind, Randomized Trial of 'Set and Setting': a Translational Study in Healthy VolunteersClinicalTrials.gov · 2026-06-04The Role of the Subjective Experience in Supporting Positive Effects Following Psilocybin: a Randomized, Controlled Clinical Trial Using Risperidone in Healthy AdultsClinicalTrials.gov · 2026-06-02Patient perceptions towards psychedelics for musculoskeletal pain: A cross-sectional surveymedRxiv · 2026-06-01Impact of formulation variables on the quality attributes of psilocybin-loaded oral thin films for early-phase developmentJournal of Drug Delivery Science and Technology · 2026-06-01Therapeutic advances in fibromyalgia: one year in review 2026.Clinical and experimental rheumatology · 2026-06-01Effects of psilocybin on sleep quality and brain microstructure in chronic cluster headacheJournal of Psychopharmacology · 2026-05-29Retail Availability of Intoxicating Cannabis and Mushroom Products Across Eleven U.S. Cities: Sales Persist Despite Prohibitions.Journal of studies on alcohol and drugs · 2026-05-28Targeting Reward Circuits: Psilocybin as a Novel Therapy for Residual AnhedoniaClinicalTrials.gov · 2026-05-27Long-Term Efficacy of Psilocybin with Adjunct Psychotherapy in Treatment-Resistant Major Depression: 6- and 12-Month Naturalistic Follow-Up of a Phase 2b TrialPsychotherapy and Psychosomatics · 2026-05-27Catatonia Associated With First-Time Psilocybin Exposure: A Case ReportCureus · 2026-05-27The Safety and Acceptability of Psilocybin With Support and With Massed Prolonged Exposure Therapy for PTSDClinicalTrials.gov · 2026-05-26Epigenome-wide association study of psilocybin-induced methylome changes in alcohol use disorderTranslational Psychiatry · 2026-05-26Effects of Psilocybin With Psychological Support on Anhedonia in Treatment-resistant Depression: a Randomized Controlled Pilot TrialClinicalTrials.gov · 2026-05-22Psilocybin-facilitated Treatment for Cocaine UseClinicalTrials.gov · 2026-05-18Association Between Lifetime Hallucinogen Use and Valvular Heart Disease: Findings from the All of Us Research Program.Journal of psychoactive drugs · 2026-05-18Psilocybin-assisted Therapy for Post-Traumatic Stress Disorder in Survivors of Intimate Partner ViolenceClinicalTrials.gov · 2026-05-14Synthesis of Amines for Active Pharmaceutical Ingredients Using the Whole-Cell Factory Saccharomyces Cerevisae.Chembiochem: a European journal of chemical biology · 2026-05-14Inaugural year of regulated psilocybin services in Oregon: safety, motivations, and utilizationFrontiers in Psychiatry · 2026-05-13Psilocybin for Treatment of Obsessive Compulsive DisorderClinicalTrials.gov · 2026-05-12A Phase 2b/3, Multicentre, Randomised, Double-blind, Controlled Trial, With an Open Label Extension, to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress DisorderClinicalTrials.gov · 2026-05-12Safety and Efficacy of Psilocybin in the Management of Treatment-Resistant Depression: A Systematic ReviewResearch Square · 2026-05-11The Safety and Efficacy of Psilocybin Therapy Compared to Low-dose Control in Reducing Depressive Symptoms in Patients With COPD, ALS, MS, or APD.ClinicalTrials.gov · 2026-05-08Neural correlates of insight on psilocybin: a within-subjects, healthy volunteer studyJoCN Forum · 2026-05-08Does Psilocybin Require Psychedelic Effects to Treat Depression? A 4-Week, Double-Blind, Proof-of-Concept Randomized Controlled TrialClinicalTrials.gov · 2026-05-07The magic of mushrooms: psilocybin influences behavior in the mangrove rivulus fish, Kryptolebias marmoratusFrontiers in Behavioral Neuroscience · 2026-05-07A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of up to Two Doses of Psilocybin for the Treatment of Major Depressive Disorder in Adults With CancerClinicalTrials.gov · 2026-05-06Induction Protocol for Psilocybin-Assisted Therapy in Treatment-Resistant Depression (TRD): A Pilot StudyClinicalTrials.gov · 2026-05-06A Phase 2 Randomized Study Examining the Safety, Feasibility, and Effectiveness of Masking Psilocybin Therapy With General Anesthesia in Major Depressive DisorderClinicalTrials.gov · 2026-05-06An Exploratory Pilot Study of Palliadelic Treatment to Reduce Psychological Distress in People With Pancreatobiliary and Other Advanced Gastrointestinal CancersClinicalTrials.gov · 2026-05-06Psilocybin-Assisted Therapy for Treatment-Resistant Depression in Bipolar II Disorder: A Randomized Controlled TrialClinicalTrials.gov · 2026-05-01Sa1731 A PILOT STUDY OF OPEN-LABEL PSILOCYBIN-ASSISTED THERAPY IN TREATMENT-REFRACTORY IBSGastrointestinal Endoscopy · 2026-05-01Profiling the Cell-Type Specific Effects of Psilocybin in Medial Prefrontal CortexhBiological Psychiatry · 2026-05-01Pure psilocybin reduces reward-associated preference while mushroom extract shows transient exploratory effects in ratsRevSALUS - Revista Científica da Rede Académica das Ciências da Saúde da Lusofonia · 2026-05-01SAT-219 Hepatic 5-HT2B receptor antagonism mediates the anti-steatotic and antifibrotic effects of psilocybin in preclinical MASH modelsJournal of Hepatology · 2026-05-01High dose of psilocybin induces acute behavioral changes without inducing conditioned place preference in Sprague-Dawley rats.Journal of psychopharmacology (Oxford, England) · 2026-05-01Insights from the psychedelic experience integration session: Verbatims differentiate 3-month abstinence in alcohol use disorder with depressive symptoms.Journal of affective disorders · 2026-05-01Advancing cancer neuroscience through stress modulation: Interdisciplinary potential of psilocybin and ketamineGeneral Hospital Psychiatry · 2026-05-01A randomized clinical trial of repeated doses of psilocybin for the treatment of obsessive-compulsive disorderJournal of Psychopharmacology · 2026-05-01Efficacy and Safety of Psilocybin in Treatment-Resistant Major DepressionJAMA Psychiatry · 2026-05-01Microdosing psilocybin for major depressive disorder: study protocol for a phase II double-blind placebo-controlled randomised partial crossover trial - CORRIGENDUMBJPsych Open · 2026-05-01Lysergic Acid Diethylamide (LSD) in Palliative Care: a Randomised, Double-blind, Active-placebo Controlled Phase II Study (LPC-Study)ClinicalTrials.gov · 2026-04-29A Double-blind, Randomized Trial Examining the Preliminary Efficacy of Psilocybin Therapy for People With Chronic Low Back PainClinicalTrials.gov · 2026-04-29“Large-Scale and Local Functional Connectivity Changes Following Psilocybin Administration in Methamphetamine Use DisorderAmerican Journal of Neuroradiology · 2026-04-24Psilocybin ameliorates neuropathic pain-like behaviour in mice and facilitates gabapentin-mediated analgesiaCommunications Biology · 2026-04-24Psilocybin-Enhanced Psychotherapy for Methamphetamine Use DisorderClinicalTrials.gov · 2026-04-22A Randomized, Double-Blind Study of Single-Dose Psilocybin for Major Depressive Disorder (MDD)ClinicalTrials.gov · 2026-04-22Toward Patient-Tailored Care for Treatment-Resistant Depression: A Pilot Patient-Preference Clinical Trial of Music and Mindfulness in Psilocybin-Assisted PsychotherapyClinicalTrials.gov · 2026-04-22Case Report: Repeated low doses of psilocybin reduce perceived symptom severity but fail to restore cognitive flexibility in a case of severe obsessive-compulsive disorder: an observational case study of identical twinsFrontiers in Psychiatry · 2026-04-21Impact of psilocybin and Psilocybe cubensis extract on gut microbiota in Wistar Han ratsScience Letters · 2026-04-17Psilocybin and Psilocybe cubensis extract exhibit divergent behavioural and toxicological effects in ratsScience Letters · 2026-04-17Effects of a single dose of psilocybin on diet-induced weight loss in obese miceTranslational Psychiatry · 2026-04-14CAPSI - Cancer Related Major Depression Treated With a Single Dose of Psilocybin: A Multicenter Randomized Placebo Controlled Double Blind Clinical TrialClinicalTrials.gov · 2026-04-13Observing the mind under psychedelics: conceptual metaphors used following four once-weekly macrodoses of psilocybinPhilosophical Psychology · 2026-04-10Role of Experience, Conscious Awareness, and Plasticity in Psilocybin's Behavioral Effects - Follow-Up Study (The RECAP 2 Study)ClinicalTrials.gov · 2026-04-03Acute Analgesic Effects of DMT on Experimentally Induced Acute Nociceptive Pain, Hyperalgesia and Allodynia in Healthy ParticipantsClinicalTrials.gov · 2026-04-02Effects of Psilocybin in Obsessive Compulsive DisorderClinicalTrials.gov · 2026-04-02Consistency of protocol and safety data reporting in clinical trial registrations and corresponding publications of interventions involving MDMA and psilocybinJournal of Clinical Epidemiology · 2026-04-01An international mega-analysis of psychedelic drug effects on brain circuit function.Nature medicine · 2026-04-01Psychedelic-assisted pharmacotherapy: clinical applications and regulatory considerations.Expert opinion on pharmacotherapy · 2026-04-01The astrocytes in the prefrontal cortex contribute to the rapid antidepressant-like effects of psilocybin in the chronic restraint stress mouse modelProgress in Neuro-Psychopharmacology and Biological Psychiatry · 2026-04-01Engaging Mood Brain Circuits With Psilocybin: a Randomized Neuroimaging Trial in DepressionClinicalTrials.gov · 2026-03-30Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use DisorderClinicalTrials.gov · 2026-03-30Psilocybe Cubensis Mushrooms With or Without Fluoxetine for Refractory DepressionClinicalTrials.gov · 2026-03-27The QUANTUM Trip Trial - Psilocybin-assisted Therapy for Reducing Alcohol Intake in Patients With Alcohol Use Disorder: A Randomized, Double-blinded, Placebo-controlled Clinical Trial.ClinicalTrials.gov · 2026-03-24Elucidating the Relevance of the Psychedelic Experience to Psilocybin's Anti-Anhedonic Effects: A Randomized, Open-Label, Cross-Over Functional Magnetic Resonance Imaging TrialClinicalTrials.gov · 2026-03-24Precision Phenotyping of Behavioral Risk and Response to Electromagnetic and Psychedelic TherapiesClinicalTrials.gov · 2026-03-20Psychedelics in functional disorders: A scoping review.Progress in neuro-psychopharmacology & biological psychiatry · 2026-03-20Psilocybin retail stores in Canada: Changes in availability, commercialization, and geographic distributionCanadian Journal of Public Health · 2026-03-19Explainable AI framework for psilocybin depression treatment optimizationFrontiers in Computer Science · 2026-03-16Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use DisorderClinicalTrials.gov · 2026-03-13Differential Effects of Acute and Chronic Fluoxetine on Psychedelic-Induced Behavior in Mice: Implications for Clinical Trials.ACS pharmacology & translational science · 2026-03-13Exploratory Study of the Effects of Low-Dose Psilocybin on Sensory Processing, Neurophysiological Arousal, and Emotional HealthClinicalTrials.gov · 2026-03-11Psilocybin-facilitated Treatment for Chronic PainClinicalTrials.gov · 2026-03-11Safety, Feasibility, and Tolerability of Psilocybin Treatment for Individuals With Functional Impairment Related to Mood, Anxiety, Trauma and/or Addiction Symptoms: An Open-label Proof-of-concept StudyClinicalTrials.gov · 2026-03-11Oregon's Emerging Psilocybin Services Workforce: A Survey of the First Legal Psilocybin Facilitators and Their Training ProgramsPsyArXiv · 2026-03-11The Therapeutic Potential of Psilocybin in Anorexia Nervosa in Young AdultsClinicalTrials.gov · 2026-03-06Pilot Proof of Concept Study Evaluating the Potential Psilocybin Assisted Psychotherapy (PAP) as a Therapeutic Tool for Patients Suffering From Severe Irritable Bowel Syndrome.ClinicalTrials.gov · 2026-03-05A Phase 2b Double-blind, Randomized, Low-dose Comparator-controlled Clinical Trial to Assess the Efficacy and Safety of NPX-5 in Psilocybin-assisted Psychotherapy for the Treatment of Adjustment Disorder Associated With Cancer.ClinicalTrials.gov · 2026-03-03Study of Psilocybin for Anorexia in Young AdultsClinicalTrials.gov · 2026-03-03Psilocybin-induced alterations in EEG power, connectivity and network dynamics in healthy subjects: Correlations with subjective experience and implications for therapeutic applicationsProgress in Neuro-Psychopharmacology and Biological Psychiatry · 2026-03-01Psychedelic therapy and cultural humility.Translational psychiatry · 2026-02-27Does Psilocybin Change Synaptic Density in the Brains of Patients With Amnestic Mild Cognitive ImpairmentClinicalTrials.gov · 2026-02-25The Effects of Psilocybin in Healthy Volunteers: Psychological, Biochemical and Electrophysiological Biomarkers.ClinicalTrials.gov · 2026-02-25Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder: a Randomized Double-blind TrialClinicalTrials.gov · 2026-02-23Safety for Home Administration of Microdose Psilocybin UseClinicalTrials.gov · 2026-02-23Investigation of Psychedelic Effects in Psychoactive SubstancesClinicalTrials.gov · 2026-02-23Delayed psilocybin treatment after repeated mild traumatic brain injury recovers chronic behavioural deficits, reduces microglial density, and enhances hippocampal neurogenesis in ratsResearch Square · 2026-02-23Safety and Efficacy of Microdosing Psilocybin over 8 Weeks for Major Depressive Disorder: A Randomized Clinical TrialResearch Square · 2026-02-23Microdosing psilocybin for major depressive disorder: study protocol for a phase II double-blind placebo-controlled randomised partial crossover trial.BJPsych open · 2026-02-16Ischemia-Induced Neurodegeneration in Glaucoma: Mechanistic Insights and Translational Opportunities for Psychoplastogen-Based Therapies.Pharmaceuticals (Basel, Switzerland) · 2026-02-14A Phase 1 Translational Study to Assess Brain Activity Using Functional Magnetic Resonance Imaging (fMRI) and to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of MLS101 (Psilocybin) in Healthy VolunteersClinicalTrials.gov · 2026-02-13Psychedelic Healing: Adjunct Therapy Harnessing Opened MalleabilityClinicalTrials.gov · 2026-02-13Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder: A Pilot Randomized Clinical TrialClinicalTrials.gov · 2026-02-12Psilocybin-Assisted Cognitive Behavioral Therapy for DepressionClinicalTrials.gov · 2026-02-12Design, Synthesis, and Pharmacokinetic Profiling of Fluorinated Reversible N -Alkyl Carbamate Derivatives of Psilocin for Sub-Hallucinogenic Brain ExposureJournal of Medicinal Chemistry · 2026-02-12Time-Dependent Effects of Rapid-Acting Antidepressants in iPSC-Derived Neurons from Treatment-Resistant Depression and Healthy Volunteers.Research square · 2026-02-12Safety and Psychological Effects of Psilocybin and D-Serine Formulation in Healthy VolunteersClinicalTrials.gov · 2026-02-05A Phase 2a, Open-label, Pilot Study to Assess the Safety and Efficacy of Oral Psilocybin (TRP-8802) Administration in Concert With Psychotherapy Among Adult Patients With Irritable Bowel Syndrome: A Randomized Delayed Treatment Control DesignClinicalTrials.gov · 2026-02-05Psilocybin AsSisted pSychotherapy for the treatmENt of Gambling disordER: a Pilot StudyClinicalTrials.gov · 2026-02-05We Licked the Toads so You Don't Have to: A Comprehensive Analysis of the Chemical Syntheses of the Classical Psychedelics Bufotenin(e) and 5-Methoxy-N,N-Dimethyltryptamine.ChemMedChem · 2026-02-01Regarding "The molecular mechanisms through which psilocybin prevents suicide: evidence from network pharmacology and molecular docking analyses".Translational psychiatry · 2026-01-31Psychedelics in psychiatric treatment: a literature reviewQuality in Sport · 2026-01-26A Phase 2 Trial of Psilocybin as an Adjunctive Treatment for OUD Patients Who Continue to Use Illicit Opioids Despite Adherence to Methadone TreatmentClinicalTrials.gov · 2026-01-23Low, non-psychedelic doses of psilocybin as a novel treatment for MASLD, obesity and type 2 diabetes via 5-HT2B receptor-dependent mechanismsRepository for Publications and Research Data (ETH Zurich) · 2026-01-20Psilocybin for Treatment-Resistant OCD: A Randomized Controlled TrialPsyArXiv · 2026-01-15Behavioral and Neural Mechanisms Supporting Psilocybin-assisted Therapy for Phantom Limb PainClinicalTrials.gov · 2026-01-09From trials to clinics: investigators' perspectives on translating psychedelic research into clinical care.Translational behavioral medicine · 2026-01-07An open-label pilot study of psilocybin-assisted therapy for binge eating disorder.Journal of eating disorders · 2026-01-03Additional file 1 of An open-label pilot study of psilocybin-assisted therapy for binge eating disorderFigshare · 2026-01-01Additional file 2 of An open-label pilot study of psilocybin-assisted therapy for binge eating disorderFigshare · 2026-01-01Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE): Results of a randomized active placebo-controlled trialNeuroscience Applied · 2026-01-01Psilocybin for major depressive disorder: An updated systematic review and meta-analysis of randomized clinical trials.Journal of psychopharmacology (Oxford, England) · 2026-01-01Global Trends in Psychedelic Microdosing: Demographics, Substance Testing Behavior, and Patterns of Use.Journal of psychoactive drugs · 2026-01-01Toward Standardized Products Containing Biomass of Psilocybe Cubensis Fungi.Journal of AOAC International · 2026-01-01Single-dose psilocybin promotes cell-type-specific changes of neurons in the orbitofrontal cortex.Neurotherapeutics: the journal of the American Society for Experimental NeuroTherapeutics · 2026-01-01